EASL 2025

EASL 2025
May 07-10, 2025
Amsterdam, Netherlands

The European Association for the Study of the Liver®.

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (23)

    Sodium Taurocholate Cotransporting Polypeptide Intronic Polymorphism rs17556915 Had No Impact on Hepatitis Delta Virus RNA Levels and Bulevirtide Response in Patients Treated With Bulevirtide

    • Author(s): Liu, Y
    • bulevirtide
    • Liver Diseases
    • Poster

    Patient characteristics and treatment patterns amongst hepatitis D patients: results from a real-world survey in Europe

    • Author(s): Buti, M
    • bulevirtide
    • Liver Diseases
    • Poster

    The SVR10K Hepatitis C study: final results show 98.9% SVR in 7,000 patients treated with SOF/VEL in Asia, Latin America, Middle East, Nordic and Southern Europe

    • Author(s): Aleman, S
    • epclusa
    • Liver Diseases
    • Poster

    Safety of seladelpar in primary biliary cholangitis patients with cirrhosis and clinical signs of portal hypertension: data from the ENHANCE and RESPONSE studies

    • Author(s): Gulamhusein, A
    • livdelzi
    • Fibrosis
    • Poster

    Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with bulevirtide monotherapy in the MYR 301 study

    • Author(s): Aleman, S
    • bulevirtide
    • Liver Diseases
    • Oral

    Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with moderate hepatic impairment and in matched control participants with normal hepatic function

    • Author(s): Kumar, P
    • bulevirtide
    • Liver Diseases
    • Poster

    Safety, tolerability and immunogenicity of GS-2829 and GS-6779, a novel arenaviral vectored therapeutic hepatitis B vaccine: results from a phase 1a study in healthy participants

    • Author(s): Gane, EJ
    • other
    • Liver Diseases
    • Poster

    Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatement follow-up

    • Author(s): Wedemeyer, H
    • bulevirtide
    • Liver Diseases
    • Oral

    Achieving undetectable hepatitis delta virus RNA at end of therapy with bulevirtide 10 mg/day with or without with pegylated interferon alpha is strongly associated with post-treatment virologic response in chronic hepatitis delta

    • Author(s): Zoulim, F
    • bulevirtide
    • Liver Diseases
    • Oral

    Efficacy and safety of seladelpar in patients previously treated with fibrates or OCA

    • Author(s): Villamil, A
    • livdelzi
    • Fibrosis
    • Poster

    Pharmacokinetics, safety, and tolerability of seladelpar in people with renal impairment

    • Author(s): Zhou, J
    • livdelzi
    • Fibrosis
    • Poster

    Clinical meaningful change of pruritus numeric rating scale in adults with primary biliary cholangitis with moderate-to-severe pruritus

    • Author(s): Levy, C
    • livdelzi
    • Fibrosis
    • Poster

    Impact of long-term tenofovir-based treatment on hepatocellular carcinoma risk in patients with chronic hepatitis B using the reREACH-B score

    • Author(s): Lim, YS
    • vemlidy
    • viread
    • Liver Diseases
    • Poster

    Paediatric pharmacokinetic-pharmacodynamic extrapolation to identify suitable bulevirtide doses for children and adolescents with chronic hepatitis delta

    • Author(s): Kumar, P
    • bulevirtide
    • Liver Diseases
    • Poster

    Seladelpar treatment of patients with primary biliary cholangitis improves the GLOBE score and predicts improved transplant-free survival

    • Author(s): Hansen, B
    • livdelzi
    • Fibrosis
    • Poster

    Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis delta with and without virologic response

    • Author(s): Brunetto, M
    • bulevirtide
    • Liver Diseases
    • Poster

    Impact of long-term oral antiviral treatment on hepatocellular carcinoma risk in patients with chronic hepatitis B who are hepatitis B e antigen positive using the PAGED-B score

    • Author(s): Lim, YS
    • vemlidy
    • viread
    • Liver Diseases
    • Poster

    Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with severe renal impairment and in matched control participants with normal renal function

    • Author(s): Kumar, P
    • bulevirtide
    • Liver Diseases
    • Poster

    Patient-reported outcomes measuring an individual’s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial

    • Author(s): Chong, K
    • bulevirtide
    • Liver Diseases
    • Poster

    A mathematical viral load model characterises the exposure-response relationship between bulevirtide and hepatitis delta virus and identifies the minimum duration of on-treatment viral load monitoring required for accurate prediction of long-term virologi

    • Author(s): Kumar, P
    • bulevirtide
    • Liver Diseases
    • Poster

    Healthcare resource use (HCRU) and cost impact of potential drug-drug interactions (DDIs) among HCV patients receiving Direct-Acting Antivirals (DAAs) concomitantly with antipsychotic drugs in the US

    • Author(s): Makhija, D
    • epclusa
    • Liver Diseases
    • Poster

    Psychometric evaluation of the pruritus numeric rating scale in patients with primary biliary cholangitis with moderate-to-severe pruritus

    • Author(s): Kremer, A
    • livdelzi
    • Fibrosis
    • Poster

    Change in pruritus in patients with primary biliary cholangitis and moderate-to-severe pruritus: a pooled analysis from the Response and Enhance studies

    • Author(s): Jones, D
    • livdelzi
    • Fibrosis
    • Poster